NCT01316185TerminatedPhase 1
An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)
Eiger BioPharmaceuticals1 site in 1 country3 target enrollmentStarted: January 2011Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- Change in HDV-RNA
Study Overview
Brief Summary
The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.
Detailed Description
This is an open-label, phase 1b, proof-of-concept study to assess the safety and efficacy of EBP921, a prenylation inhibitor, in subjects chronically infected with delta hepatitis. Subjects will be randomized to receive one of two different doses of EBP921. Dosing will occur over 28-days and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA via PCR assay. In addition, safety lab data will also be collected along with surveillance monitoring of HBV activity.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men and women age 18 or older with the capacity to give written informed consent
- •Patients with compensated chronic HDV infection as indicated by presence of anti-HDV in serum.
- •Liver biopsy should be performed within one-year of study screening and graded using the Knodell scoring system.
- •Presence of HDV antigen in liver tissue or HDV-RNA in serum.
- •Active HBV replication will not exclude patients.
- •Previous therapy with standard alpha-interferon or peginterferon will not exclude patients.
- •Patients who are HBV therapy-naïve or who previously received HBV antiviral therapy will be eligible. Patients currently taking HBV antiviral therapy will e considered on a case basis.
- •Female subjects of reproductive potential and female partners of male subjects should be on two reliable forms of contraception from the start of the study until 60 days from the end of EBP921 dosing.
Exclusion Criteria
- •Severe neuropsychiatric disorders
- •History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune-mediated disease
- •Pregnant or breast-feeding patients or the inability to practice adequate contraception during the conduct of the study
- •Underlying autoimmune/immune-deficiency disease (e.g., lupus, sarcoidosis, celiac disease, HIV antibody positive, AIDS)
- •Chronic (> 4 weeks duration) diarrhea
- •Body weight > 128 kg and < 40 kg
- •Uncompensated cirrhosis
- •Absolute neutrophil count less than 1500 per cubic millimeter
- •Platelet count less than 90,000 per cubic millimeter
- •Evidence of concurrent HCV infection with positive serum HCVRNA
- •Evidence of hepatocellular carcinoma
- •Active substance abuse (alcohol, inhaled or injected drugs) within the past 12 months
- •Diagnosis of malignancy in the previous five years excluding superficial dermatologic malignancies
- •Any experimental therapy in the previous 6 months prior to enrollment.
- •Patients with a history of multiple drug resistant HBV
- •Patients receiving interferon therapy for any reason.
Arms & Interventions
Group 1
Experimental
Low Dose for 28 days: n=4
Intervention: EBP921 (Drug)
Group 2
Experimental
High Dose for 28 days; n=4
Intervention: EBP921 (Drug)
Outcomes
Primary Outcomes
Change in HDV-RNA
Time Frame: 28 days
The primary efficacy endpoint will be the median change in HDV-RNA from baseline to HDV RNA nadir as measured by quantitative PCR during the 28-day dosing period.
Secondary Outcomes
- Change in HDV RNA from baseline to Day 7, 14, 28 and post therapy weeks 1,2,4,8(8 Weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)DiarrheaNCT00097422Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Terminated
Phase 1
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisCompensated CirrhosisPrimary Sclerosing CholangitisNCT04060147Gilead Sciences11
Not yet recruiting
Phase 2
MRG-001 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisLou Gehrig DiseaseMotor Neuron AtrophyMotor Neuron DiseaseNCT06315608MedRegen LLC10
Completed
Phase 1
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast CancerLocally Recurrent and Metastatic Breast CancerNCT00322400Amgen46
Completed
Phase 2
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT02426372Qu Biologics Inc.11